|
US20110105995A1
(en)
*
|
2008-01-16 |
2011-05-05 |
Zhu Ting F |
Uniform-sized, multi-drug carrying, and photosensitive liposomes for advanced drug delivery
|
|
EP2566335B1
(en)
|
2010-05-05 |
2016-06-29 |
Prolynx Llc |
Controlled release of active compounds from macromolecular conjugates
|
|
BR112013031556B1
(pt)
|
2011-06-06 |
2022-03-29 |
Starpharma Pty Ltd |
Macromoléculas, uso das mesmas para tratar ou suprimir o crescimento de um câncer e composições farmacêuticas
|
|
KR102109067B1
(ko)
|
2011-09-07 |
2020-05-13 |
프로린크스 엘엘시 |
생분해성 교차결합을 가지는 하이드로젤
|
|
WO2013036857A1
(en)
*
|
2011-09-07 |
2013-03-14 |
Prolynx Llc |
Sulfone linkers
|
|
CA2873112A1
(en)
*
|
2012-05-11 |
2013-11-14 |
Alexander Krantz |
Site-specific labeling and targeted delivery of proteins for the treatment of cancer
|
|
WO2014116717A1
(en)
*
|
2013-01-22 |
2014-07-31 |
Prolynx Llc |
Sealants having controlled degradation
|
|
US10130711B2
(en)
|
2013-06-19 |
2018-11-20 |
The Regents Of The University Of California |
Chemical structures for localized delivery of therapeutic agents
|
|
SG10201803370XA
(en)
*
|
2013-10-22 |
2018-06-28 |
Prolynx Llc |
Conjugates of somatostatin and its analogs
|
|
JP6701077B2
(ja)
*
|
2013-12-19 |
2020-05-27 |
シアトル ジェネティックス， インコーポレイテッド |
標的化薬物結合体と使用するためのメチレンカルバメートリンカー
|
|
ES2880468T3
(es)
|
2014-03-14 |
2021-11-24 |
Univ California |
Conjugados de TCO y métodos para el suministro de agentes terapéuticos
|
|
LT3400019T
(lt)
|
2016-01-08 |
2022-12-12 |
Ascendis Pharma Growth Disorders A/S |
Cnp provaistai su prie žiedo fragmento prijungtu nešikliu
|
|
MX2018008061A
(es)
|
2016-01-08 |
2018-08-23 |
Ascendis Pharma Growth Disorders As |
Profarmacos de peptido natriuretico tipo c (cnp) con porciones portadoras grandes.
|
|
WO2017118707A1
(en)
|
2016-01-08 |
2017-07-13 |
Ascendis Pharma Growth Disorders A/S |
Controlled-release cnp agonists with reduced side-effects
|
|
IL259827B2
(en)
|
2016-01-08 |
2025-07-01 |
Ascendis Pharma Growth Disorders As |
Controlled-release CNP agonists with low initial NPR-B activity
|
|
NZ743487A
(en)
|
2016-01-08 |
2023-02-24 |
Ascendis Pharma Growth Disorders As |
Controlled-release cnp agonists with increased nep stability
|
|
IL297375B2
(en)
|
2016-01-08 |
2024-02-01 |
Ascendis Pharma Growth Disorders As |
Controlled-release CNP agonists with low NPR–C binding
|
|
MX2018009938A
(es)
|
2016-03-01 |
2019-03-14 |
Ascendis Pharma Bone Diseases As |
Profarmacos de hormona paratiroidea (pth).
|
|
EP3922269A1
(en)
*
|
2016-03-16 |
2021-12-15 |
Prolynx LLC |
Extended release conjugates of exenatide analogs
|
|
US11896671B2
(en)
|
2016-07-13 |
2024-02-13 |
Ascendis Pharma A/S |
Conjugation method for carrier-linked prodrugs
|
|
MA46428B1
(fr)
|
2016-09-29 |
2025-02-28 |
Ascendis Pharma Bone Diseases A/S |
Composés de pth à libération contrôlée
|
|
CN109789189B
(zh)
|
2016-09-29 |
2024-01-23 |
阿森迪斯药物骨疾病股份有限公司 |
控释pth化合物的剂量方案
|
|
HUE062117T2
(hu)
|
2016-09-29 |
2023-09-28 |
Ascendis Pharma Growth Disorders As |
Kombinációs terápia szabályozott felszabadulású CNP agonistákkal
|
|
EP3518961B1
(en)
|
2016-09-29 |
2023-02-22 |
Ascendis Pharma Bone Diseases A/S |
Pth compounds with low peak-to-trough ratios
|
|
TWI773730B
(zh)
|
2017-02-22 |
2022-08-11 |
瑞典商阿斯特捷利康公司 |
治療性樹枝狀聚合物
|
|
SG10202107829YA
(en)
|
2017-03-22 |
2021-08-30 |
Genentech Inc |
Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
|
|
JOP20190245A1
(ar)
|
2017-04-20 |
2019-10-15 |
Novartis Ag |
أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
|
|
WO2019058367A1
(en)
*
|
2017-09-19 |
2019-03-28 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
LIPOPHILIC PRODRUGS BASED ON PEPTIDES
|
|
US11965041B2
(en)
|
2017-09-19 |
2024-04-23 |
Technische Universitaet Muenchen |
N-methylated cyclic peptides and their prodrugs
|
|
MX2020007306A
(es)
|
2018-01-12 |
2020-09-25 |
Prolynx Llc |
Tratamiento sinergico de cancer.
|
|
EP3765096A1
(en)
*
|
2018-03-12 |
2021-01-20 |
Boston Scientific Scimed Inc. |
Scavenging methods, and scavenging system for radiocontrast agents
|
|
EP3773681A1
(en)
|
2018-03-28 |
2021-02-17 |
Ascendis Pharma A/S |
Conjugates
|
|
WO2019185705A1
(en)
|
2018-03-28 |
2019-10-03 |
Ascendis Pharma A/S |
Il-2 conjugates
|
|
PL3793587T3
(pl)
|
2018-05-18 |
2025-09-22 |
Ascendis Pharma Bone Diseases A/S |
Dawka początkowa koniugatów PTH
|
|
BR112021000658A2
(pt)
|
2018-07-19 |
2021-04-13 |
Starpharma Pty Ltd |
Dendrímero, composições, composição farmacêutica, método de tratamento de câncer, uso de dendrímero, método, uso, dendrímero ou composição, processo de produção de dendrímero e intermediários para a produção de dendrímero
|
|
US12071517B2
(en)
|
2018-07-19 |
2024-08-27 |
Starpharma Pty Ltd. |
Therapeutic dendrimer
|
|
IL281690B2
(en)
|
2018-09-26 |
2025-01-01 |
Ascendis Pharma As |
New hydrogel bracelets
|
|
WO2020064847A1
(en)
|
2018-09-26 |
2020-04-02 |
Ascendis Pharma A/S |
Degradable hyaluronic acid hydrogels
|
|
WO2020064844A1
(en)
|
2018-09-26 |
2020-04-02 |
Ascendis Pharma A/S |
Treatment of infections
|
|
AR116566A1
(es)
|
2018-10-03 |
2021-05-19 |
Novartis Ag |
Administración sostenida de polipéptidos similares a la angiopoyetina 3
|
|
BR112021010043A2
(pt)
|
2019-01-04 |
2021-10-26 |
Ascendis Pharma Oncology Division A/S |
Níveis de fármaco locais sustentados para agonistas imunes inatos
|
|
EP3906065B1
(en)
|
2019-01-04 |
2025-04-30 |
Ascendis Pharma Oncology Division A/S |
Prr agonist for use in the treatment of cancer
|
|
AU2020204786A1
(en)
|
2019-01-04 |
2021-06-10 |
Ascendis Pharma Oncology Division A/S |
Induction of sustained local inflammation
|
|
TW202500188A
(zh)
|
2019-01-04 |
2025-01-01 |
丹麥商阿仙帝斯製藥公司 |
模式辨別受體(pattern recognition receptor)促效劑的共軛物
|
|
EP3923906A1
(en)
|
2019-02-11 |
2021-12-22 |
Ascendis Pharma Growth Disorders A/S |
Dry pharmaceutical formulations of cnp conjugates
|
|
CA3129357A1
(en)
|
2019-02-11 |
2020-08-20 |
Ascendis Pharma Bone Diseases A/S |
Liquid pharmaceutical formulations of pth conjugates
|
|
WO2020206358A1
(en)
|
2019-04-05 |
2020-10-08 |
Prolynx Llc |
Improved conjugation linkers
|
|
KR20220004134A
(ko)
*
|
2019-04-26 |
2022-01-11 |
프로린크스 엘엘시 |
서방형 사이토카인 컨쥬게이트
|
|
WO2020247151A1
(en)
|
2019-06-05 |
2020-12-10 |
Boston Scientific Scimed, Inc. |
Click chemistry capturable platinum-based antineoplastic agents
|
|
AU2020295721B2
(en)
*
|
2019-06-21 |
2025-04-03 |
Ascendis Pharma A/S |
Conjugates of π-electron-pair-donating heteroaromatic nitrogen-comprising compounds
|
|
WO2020254612A1
(en)
|
2019-06-21 |
2020-12-24 |
Ascendis Pharma Oncology Division A/S |
Controlled-release tyrosine kinase inhibitor compounds with localized pd properties
|
|
WO2020254607A1
(en)
|
2019-06-21 |
2020-12-24 |
Ascendis Pharma Oncology Division A/S |
Anti-ctla4 compounds with localized pd properties
|
|
EP3986479A1
(en)
|
2019-06-21 |
2022-04-27 |
Ascendis Pharma Oncology Division A/S |
Anti-ctla4 conjugates
|
|
WO2020254617A1
(en)
|
2019-06-21 |
2020-12-24 |
Ascendis Pharma Oncology Division A/S |
Anti-ctla4 compounds with localized pk properties
|
|
CA3143278A1
(en)
|
2019-06-21 |
2020-12-24 |
Ascendis Pharma Oncology Division A/S |
Tyrosine kinase inhibitor conjugates
|
|
WO2020254613A1
(en)
|
2019-06-21 |
2020-12-24 |
Ascendis Pharma Oncology Division A/S |
Controlled-release tyrosine kinase inhibitor compounds with localized pk properties
|
|
CA3153644A1
(en)
*
|
2019-09-30 |
2021-04-08 |
Beijing Xuanyi Pharmasciences Co., Ltd. |
Protein-macromolecule conjugates and methods of use thereof
|
|
MX2022007371A
(es)
|
2020-01-13 |
2022-07-12 |
Ascendis Pharma Bone Diseases As |
Tratamiento del hipoparatiroidismo.
|
|
CA3175974A1
(en)
|
2020-05-04 |
2021-11-11 |
Oliver Boris Stauch |
Hydrogel irradiation
|
|
MX2022014082A
(es)
|
2020-06-03 |
2022-12-07 |
Ascendis Pharma Oncology Div A/S |
Secuencias de interleucina (il-2) y usos de las mismas.
|
|
JP2023540701A
(ja)
|
2020-08-28 |
2023-09-26 |
アセンディス ファーマ オンコロジー ディヴィジョン エー／エス |
グリコシル化ｉｌ－２タンパク質及びその使用
|
|
AU2021349316A1
(en)
|
2020-09-28 |
2023-04-27 |
Ascendis Pharma Bone Diseases A/S |
Improvement of physical and mental well-being of patients with hypoparathyroidism
|
|
BR112023018802A2
(pt)
|
2021-04-01 |
2023-10-31 |
Ascendis Pharma As |
Uso de hormônio de crescimento de ação prolongada para o tratamento de doenças induzidas por inflamação
|
|
IL311539A
(en)
|
2021-09-22 |
2024-05-01 |
Ascendis Pharma Bone Diseases As |
Long-acting pth compound treatments
|
|
WO2023069510A1
(en)
*
|
2021-10-19 |
2023-04-27 |
The United States Government As Represented By The Department Of Veterans Affairs |
Cannabinoid compositions for gastroesophageal disorders
|
|
CA3236278A1
(en)
|
2021-12-13 |
2023-06-22 |
Kennett Sprogoe |
Effective doses of cnp conjugates
|
|
US20250032638A1
(en)
|
2021-12-13 |
2025-01-30 |
Ascendis Pharma Oncology Division A/S |
Novel Cancer Treatments with TLR7/8 Agonists
|
|
IL316466A
(en)
|
2022-05-23 |
2024-12-01 |
Ascendis Pharma Growth Disorders As |
Liquid pharmaceutical formulations of cnp compounds
|
|
CN114874624B
(zh)
*
|
2022-05-27 |
2023-04-07 |
深圳市博致远科技有限公司 |
一种导热吸波室温固化硅橡胶产品及其制备方法
|
|
WO2024094673A1
(en)
|
2022-11-02 |
2024-05-10 |
Ascendis Pharma Bone Diseases A/S |
Pth treatment regimen comprising two pth compounds
|
|
WO2024104922A1
(en)
|
2022-11-14 |
2024-05-23 |
Ascendis Pharma Growth Disorders A/S |
Method of improving skeletal muscle function
|
|
TW202434299A
(zh)
|
2023-01-05 |
2024-09-01 |
丹麥商阿仙帝斯製藥公司 |
製造水凝膠微球之方法
|
|
TW202430223A
(zh)
|
2023-01-05 |
2024-08-01 |
丹麥商阿仙帝斯眼科製藥有限公司 |
用於治療眼部病症之藥物結合物
|
|
WO2024184354A1
(en)
|
2023-03-06 |
2024-09-12 |
Ascendis Pharma A/S |
Multi-albumin binding compounds
|
|
AU2024232125A1
(en)
|
2023-03-06 |
2025-08-28 |
Ascendis Pharma A/S |
Compounds of drugs with an albumin binding moiety
|
|
WO2024184352A1
(en)
|
2023-03-06 |
2024-09-12 |
Ascendis Pharma A/S |
Drug compounds comprising albumin-binding moieties
|
|
AU2024240722A1
(en)
|
2023-03-20 |
2025-09-18 |
Ascendis Pharma Growth Disorders A/S |
Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia
|
|
CN121175071A
(zh)
|
2023-05-09 |
2025-12-19 |
阿森迪斯药物肿瘤股份有限公司 |
使用il-2缀合物的新型癌症治疗方法
|
|
WO2025051711A1
(en)
|
2023-09-04 |
2025-03-13 |
Ascendis Pharma Bone Diseases A/S |
Pth treatment of chronic kidney disease
|
|
WO2025208117A1
(en)
*
|
2024-03-29 |
2025-10-02 |
Maha Therapeutics, Inc. |
Cleavable ester compounds and uses thereof
|
|
WO2026013135A1
(en)
|
2024-07-10 |
2026-01-15 |
Ascendis Pharma A/S |
Albumin-binding reagents
|
|
WO2026013138A1
(en)
|
2024-07-10 |
2026-01-15 |
Ascendis Pharma A/S |
Compounds with improved albumin-binding
|
|
WO2026013136A1
(en)
|
2024-07-10 |
2026-01-15 |
Ascendis Pharma A/S |
Albumin-binding compounds
|